Ic1ccc2c(c1)N(c1ccccc1)c1cc([N-]c3ccc4nc5ccc(I)cc5[n+](-c5ccccc5)c4c3)ccc1N2
The rule of three is typically followed by orally active drugs, which have a molecular weight of <300, a c LogP of ≤3, a hydrogen bond donor count of ≤3 and a hydrogen bond acceptor count of ≤3. Does the molecule comply with the rule of three?